Skip to main
OPRX

OptimizeRx Corp (OPRX) Stock Forecast & Price Target

OptimizeRx Corp (OPRX) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

OptimizeRx is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. With a substantial majority of its revenue generated from life sciences customers, OPRX's financial success is closely tied to the overall market conditions and policy changes that may impact the biopharma industry. Despite potential risks, OPRX maintains its 2026 revenue/EBITDA outlook and expects to see a return to growth in 2027, reaffirming its market outperform rating. The company's differentiating factors, including its ability to deliver personalized electronic messages to healthcare providers and its diverse revenue streams, position OPRX for long-term success.

Bears say

OptimizeRx is facing significant challenges in the healthcare market, and its FY26 revenue guidance has been reduced due to a macro slowdown, lowered revenue from a top client, and general headwinds. While the company's connection with demand-side platforms (DSPs) has potential to drive future revenue, the timing and impact of this integration remains unclear. Additionally, persistent contraction in contracted revenues and uncertainties surrounding customer spending patterns further add to the negative outlook for the company.

OptimizeRx Corp (OPRX) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OptimizeRx Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OptimizeRx Corp (OPRX) Forecast

Analysts have given OptimizeRx Corp (OPRX) a Buy based on their latest research and market trends.

According to 7 analysts, OptimizeRx Corp (OPRX) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OptimizeRx Corp (OPRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.